Promising early results for treating metastatic prostate cancer
https://www.facingourrisk.org/XRAY/talazoparib-for-metastatic-prostate-cancer
Full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00376-4/fulltext
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- With my diagnosis of mCRPC, should I consider genetic testing for an inherited mutation?
- Should I have additional tumor testing to see what other treatments may be available for me?
- What are the treatment options for my metastatic prostate cancer?
- Is PARP inhibitor therapy appropriate for me? Am I eligible for any clinical trials of PARP inhibitors?
Open Clinical Trials
The following studies look at PARP inhibitors and similar agents for treating people with advanced prostate cancer.
- NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study examines the safety and effectiveness of an investigational treatment XL309 when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors including prostate cancer.
- NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. This study looks at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with metastatic castration-resistant prostate cancer who have been treated with at least 2 prior lines of treatment.
- NCT05417594: Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study). This study looks at a new PARP inhibitor AZD9574 given alone and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed.
Other clinical trials for people with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.